LDLR and neoplasm: Moreover, LXR agonists have also been demonstrated to increase the expression of ABCA1 and the induction of the LDLR-degrading ubiquitin E3 ligase IDOL, which leads to tumor cell apoptosis and a reduction in tumor growth in glioblastoma xenograft models (41).